Three meningococcal vaccines areavailable in the U.S. that include meningococcal polysaccharide vaccine(MPSV4), meningococcal conjugate vaccine (MCV4), serogroup B meningococcalvaccine. The vaccine is administered to 11 to 12 year olds and a booster doseis given at 16 years of age. International travelers to Mecca for Hajj,sub-Saharan Africa, and other meningococcal epidemic prone areas requiremeningococcal vaccine.
The global MeningococcalVaccines Market is estimated to account for US$ 3,341.9 Mn in terms ofvalue and is expected to reach US$ 7,732.3 Mn by the end of 2027.
Global Meningococcal VaccinesMarket: Drivers
Increasing number of travelers toHajj is expected to propel growth of the global meningococcal vaccines marketover the forecast period. For instance, according to Travelport Worldwide Ltd.,Asia Pacific recorded the highest growth in flight bookings made through globaldistribution system to airports around Mecca in 2019, recording 5% increase innumber of bookings.
Global Meningococcal VaccinesMarket: Opportunities
R&D related to meningococcalvaccination is expected to offer lucrative growth opportunities for players inthe market. For instance, in October 2019, researchers from The Children’sHospital at Westmead, Australia, reported assessment of meningococcal vaccineuptake among Hajj pilgrims.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3864
Global Meningococcal VaccinesMarket: Restraints
Maintenance of cold chains todeliver vaccines leads to high cost of vaccination, which is expected to hindergrowth of the market. Maintaining the cold chain (which comprises a series ofrefrigerators, and ice-chilled carriers maintaining temperature between 2degree Celsius and 8 degree Celsius for vaccine storage) is a major challengingtask while delivering the vaccines to the needy, especially in the developingcountries.
Key Takeaways:
The global meningococcal vaccinesmarket was valued at US$ 2,965.9 Mn in 2019 and is forecast to reach a value ofUS$ 7,732.3 Mn by 2027 at a CAGR of 12.7% between 2020 and 2027. Major factordriving the growth of global meningococcal vaccines market during the forecastperiod is increasing prevalence of meningitis, and increasing governmentinitiatives for increasing vaccinations.
Conjugate vaccines segment helddominant position in the global meningococcal vaccines market in 2019,accounting for 85.5% share in terms of value. Products approval formeningococcal conjugate vaccine candidates has supported growth of the segment.For instance, in December 2016, Pfizer Inc. received an European Commission(EC) approval for its expanded indication for Nimenrix (meningococcal group A,C, W-135, and Y conjugate vaccine), which is indicated for active immunizationagainst invasive meningococcal disease (IMD).
Private distribution segment helddominant position in the global meningococcal vaccines market in 2019,accounting for 81.3% share in terms of value, followed by governmentdistribution channel, respectively. Private vaccination centers charge forvaccines while government vaccine distribution centers provide vaccine forfree/at low price through various immunization programs. This is expected tosupport growth of the segment over the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/meningococcal-vaccines-market-3864
Market Trends
Domestic pilgrims of Hajj oftenmiss the compulsory meningococcal vaccine. For instance, according to thestudy, ‘Meningococcal Vaccine for Hajj Pilgrims: Compliance, Predictors, andBarriers’, published in MDPI Tropical Medicine and Infectious Disease, inOctober 2019, 81.7% confirmed their meningococcal vaccination status, 13.4% didnot receive the vaccine, and 4.8% were unsure.
Several state governments in theU.S. are mandating meningococcal vaccination. For instance, in January 2020,the Government of New Jersey, U.S., mandated college students to be vaccinatedagainst bacterial meningitis as a condition for attending an institution.
Regulations
Canada
Health Canada launched a newlyapproved 4CMenB vaccine in all the provinces in late 2013. On an average, thecost of Novartis’s 4CMenB vaccine Bexsero is high i.e. US$ 100, but thereimbursement pattern is yet to be established.
Biologics and Genetic TherapiesDirectorate, in collaboration with Public Health Agency of Canada, conducts apre-release test which includes quality of vaccine, safety and effectiveness.After extensive review of all supporting data, the vaccine receives marketingapproval.
Global Meningococcal VaccinesMarket: Competitive Landscape
Major players operating in theglobal meningococcal vaccines market include, Baxter International, Inc.,Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation,Novartis International AG., Pfizer, Inc., Sanofi SA, and Serum Institute ofIndia Ltd.
Global Meningococcal VaccinesMarket: Key Developments
January 2020: GlaxoSmithKline plcfunded study ‘Meningococcal B Vaccine and Meningococcal Carriage in Adolescentsin Australia’, published in the New England Journal of Medicine, reported thatthe 4CMenB vaccine had no discernible effect on the carriage of disease-causingmeningococci, including group B among Australian adolescents.
September 2019: BaxterInternational Inc. attended the Morgan Stanley 17th Annual Global HealthcareConference in New York, U.S.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3864
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
